ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

33311 results sorted by trial registration date.
  • Evaluation of a patient communication resource (Check-Backv2) in rural chronic disease settings

    The primary aim of this study is to investigate if a co-designed communication training resource for health consumers (Check-BackV2) improves patient activation levels in rural patients with chronic disease 12 weeks after a planned appointment with a health professional. The intervention is the Check-BackV2 package which has been developed to help rural patients build their skills and confidence to engage in active, two-way discussions with clinicians. The Check-BackV2 package comprises a 6-page pamphlet, a wallet card and postcard with reminders to use check-back and a link to the revised check-back website (the latter for optional viewing). Participants in the intervention group will also be sent two SMS reminders to use check-back during their next planned health appointment. The usual care group will receive no intervention during the study period. Expected outcomes are that the intervention group will have a greater improvement in patient activation, health literacy, medication adherance, and lower emergency department presentations and hospital admissions compared to the control group at follow-up time-points.

  • PREDICT-DL: Performance of Paediatric Real-time Emergency Department admission and Inpatient Care Time prediction with Deep Learning

    This is a prospective, real-world proof of concept study evaluating the performance of a continuously deployed machine learning (ML) forecasting system that generates hourly, ED-cohort–level admission and length of stay (LOS) prediction. It is set within a Paediatric Hospital, with data from the Emergency Department (ED) triage comprising the model’s features. The model will predict expected inpatient ward admissions (including surgical vs medical if possible), expected ED Short Stay Unit (ESSU) admissions, and the expected mean inpatient LOS among those expected to be admitted to the ward. The system operates in parallel to usual operations, without significant system demands and is not planned to alter clinical decision-making during the evaluation period. The outcomes for this modelling are intended for the patient flow team and bed managers only, with outputs only occurring on an ED cohort level, not on an individual patient level.

  • Home Hearing Health Checks for Meals on Wheels Clients

    There is a high prevalence of undiagnosed and untreated hearing loss among older adults. To improve access to hearing health care, the SOUND-BITES program will pilot a novel method of delivering hearing health assessments with MoW Clients. Master of Clinical Audiology students partnered with MoW Volunteers will complete hearing health checks of MoW Clients in their own homes. The hearing health checks include otoscopic examination of the ear using the Arclight otoscope and hearing loss screening using the Sound Scouts hearing screening app. MoW clients will be referred for further assessment where indicated. Education will be provided on the importance of looking after hearing health by the Audiology Students and MoW Volunteers.

  • Ultra-hypofractionated external beam radiation therapy with risk-adapted brachytherapy boost in localised prostate cancer

    What is the purpose of this study? This study is aiming to evaluate whether risk-adapted brachytherapy to the prostate, as opposed to standard brachytherapy, improves prostate cancer outcomes and reduces side effects for patients. Who is it for? Patients with localised prostate cancer, who have higher risk disease, where a combination of external beam radiation therapy and brachytherapy is recommended, are eligible to enroll onto this study. What are the details? All participants enrolled onto the study will receive the investigative treatment (risk-adapted brachytherapy) and have regular follow-up after treatment completion to assess treatment outcomes and side effects. Follow-up after treatment completion is similar to what you would have if you were not on this study and includes regular visits with your treating oncologist and regular PSA blood tests. If results from this study are favourable, it is hoped that future patients with prostate cancer will be able to have more effective radiation treatment with less side effects.

  • The effect of personalised 3D printed metamaterial insoles on plantar pressures in adults at risk of diabetes-related foot wounds.

  • Exercise program on strength, body composition, and quality of life in children who have survived acute lymphoblastic leukaemia

    This study aims to test whether a short, supervised exercise program called integrative neuromuscular training (INT) is safe, achievable, and enjoyable for children, and whether it may improve strength, movement skills, and overall physical and mental wellbeing. Who is it for? You may be eligible if you are aged 6–12 years who were diagnosed with acute lymphoblastic leukaemia, have been in remission for at least 6 months, and are within 5 years of completing treatment. Study details All participants who are eligible will take part in an individualised, supervised integrative neuromuscular training (INT) exercise program. The program involves 16 one on one exercise sessions delivered over about 8 weeks (two sessions per week), with each session lasting around 60 minutes. Sessions include a warm-up, strength and movement skill exercises, fun circuit-based activities targeting speed, balance, and core strength, and a cool down with stretching. Exercise sessions are led by a qualified exercise professional experienced in working with children and can be delivered in person or via telehealth if needed. The program is tailored to each child and adjusted over time based on their ability and comfort level, with exercise intensity monitored throughout. Participants will complete physical assessments to measure muscle strength, physical function, body composition, as well as questionnaires about physical activity and wellbeing. It is hoped that the results from this study will help develop safe and effective exercise programs that support long term health, physical function, and quality of life for children who have survived leukaemia.

  • RISE (Recovery, Information, Support and Empowerment): Feasibility of a clinician-supported SMS intervention for individuals at risk of poor recovery after acute whiplash injury

    This study aims to evaluate the feasibility of RISE, a clinician-supported SMS text message intervention designed to support recovery following whiplash-associated disorder after a road traffic crash. Participants (n=50) within 12 weeks of injury and at medium to high risk of poor recovery will be randomised (1:1) to receive either the RISE intervention or an active control condition consisting of generic health messages and access to online resources. The RISE intervention delivers tailored messages focused on recovery, information, support, and empowerment to promote self-efficacy and informed recovery. Feasibility outcomes include recruitment, retention, engagement, and acceptability, with preliminary effectiveness and feasibility of integrating multimodal data also explored. Findings will inform the design of a future definitive trial and the potential implementation of scalable early interventions for people with whiplash injury.

  • A Phase 1a/1b Dose-Escalation and Expansion Study of [¹77Lu]Lu-FAP-2286 Radioligand Therapy in Combination with Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Patients with Unresectable or Advanced Malignant Pleural Mesothelioma (MPM)

    Brief description of the study purpose This Phase 1 study is testing the safety of a new targeted radioactive treatment, [¹77Lu]Lu FAP 2286, given together with standard immunotherapy (nivolumab and ipilimumab), to find the safest dose and understand how the combination behaves in patients with malignant pleural mesothelioma. Who is it for? You may be eligible for this study if you are male or female aged 18 or over with advanced or unresectable malignant pleural mesothelioma whose cancer shows uptake on a specialised FAP PET scan and who are eligible to receive immunotherapy. Study details All participants will receive an intravenous dose of the investigational radioligand [¹77Lu]Lu FAP 2286 every 6 weeks for up to 4 cycles, alongside standard nivolumab and ipilimumab immunotherapy. The early part of the study tests increasing dose levels of the radioligand to identify the safest dose, followed by an expansion group treated at the selected dose. Participants will undergo regular blood tests, imaging (including specialised FAP PET scans), and clinical assessments to monitor safety and response. The results from this study will help determine whether combining targeted radiotherapy with immunotherapy is safe and feasible, and may inform future studies aiming to improve outcomes for people with mesothelioma.

  • Feasibility of a Diet and Lifestyle Program Guided by Real-Time Glucose Monitoring in Postmenopausal Women at Risk of Type 2 Diabetes

    The aim of this research study is to assess the feasibility of conducting a future randomised controlled trial using a continuous glucose monitor paired with an Australian mobile app that provides diet and lifestyle education, recommendations for reducing glucose spikes and support from a dietitian coach in a cohort of postmenopausal women at risk of type 2 diabetes (T2D). Empowering women with real-time glucose insights and personalised tools may enable sustainable lifestyle change. If feasible and acceptable, this model could support scalable, cost-effective interventions to reduce T2D risk in this vulnerable population.

  • Personalised Melanoma Risk Assessment in Australian Adults Using Genetic and Clinical Information for Prevention Behaviours

    The purpose of this study is to determine whether providing personalised melanoma (skin cancer) risk information based on genetic and other lifestyle factors has any influence on sun protection and skin cancer prevention behaviours in Australian adults. Who is it for? You may be eligible for this study if you are aged 18 or over and have previously enrolled in the Australasian Centre of Excellence in Melanoma Imaging and Diagnosis study (ACTRN12619001706167). Note, that you do not need to have been diagnosed with skin cancer or be at risk of skin cancer to participate in this study. Study details Participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin) to one of two groups. Participants allocated to the first group will receive personalised melanoma risk information as an electronic booklet, based on a genetic sample and additional information provided as part of the Australasian Centre of Excellence in Melanoma Imaging and Diagnosis study. Participants allocated to the second group will receive standard melanoma prevention information, based on the available guidance from the Cancer Council. Participants in both groups will be asked to complete online questionnaires at the time they enrol, and then at 3 months and 12 months after enrolment. Participants who are allocated to the second group will then be offered the option to receive a personalised melanoma risk booklet after they have completed their final questionnaires at 12 months. It is hoped this research will improve participants' willingness to engage in melanoma prevention and sun protection behaviours, which could reduce their risk of melanoma.

Tags:
  • Finding clinical trials